Introduction {#s1}
============

Mastocytosis is a disease characterized by the excessive accumulation of mast cells in at least one of several organs, including the skin, bone marrow, lymph nodes, liver, spleen, and gastrointestinal tract [@pone.0002266-Valent1]--[@pone.0002266-Escribano1]. The true incidence of mastocytosis is unknown, but the available evidence suggests that it is a rare disease, with a prevalence of no more than 0.3 per 10,000, which qualifies it as an orphan disease [@pone.0002266-DInc1], [@pone.0002266-Hogan1]. In aggressive forms of mastocytosis, the accumulation of mast cells in organs and tissues causes a loss of function and degeneration, which can decrease life expectancy. Aggressive forms of mastocytosis are rare (\<10% of all cases) and require specific treatment aimed at reducing mast cell infiltration and activity. Patients with indolent forms of mastocytosis, however, do not have a decreased life expectancy or organ damage, but they can suffer from a very wide variety of signs and symptoms, including pruritus, flushing, syncope, hypotensive shock, dizziness, abdominal pain, nausea, vomiting, diarrhea, fatigue, memory loss, depression, tachycardia, palpitations, breathing difficulties, fractures/osteoporosis, and pain in the muscles, joints, and bones [@pone.0002266-Valent1]--[@pone.0002266-Escribano1]. These systemic manifestations are believed to be due to the release of mast cell-derived mediators, such as histamine, prostaglandins, heparin, neutral proteases, acid hydrolases, chemokines, and cytokines.

Therefore, mastocytosis is now known to be a multidimensional disease with a wide variety of signs and symptoms. This has complicated its diagnosis, classification, and treatment. In 2001, to help address this problem, the World Health Organization (WHO) developed a consensus classification system for mastocytosis [@pone.0002266-Valent2]. This system separates mastocytosis into cutaneous mastocytosis (CM) and five main subtypes of systemic mastocytosis (SM), including indolent SM, SM with an associated hematologic clonal, non-mast cell lineage disease, aggressive SM, smoldering SM, and mast cell leukemia. CM is diagnosed by the presence of skin lesions and the absence of definitive systemic involvement by mast cells. In the majority of cases, a diagnosis of SM is established by evidence of mast cell infiltration in the bone marrow or, less frequently, the liver, spleen or gastrointestinal tract. Minor criteria for a diagnosis of SM can include abnormal mast cell morphologies in the bone marrow and other extracutaneous organs, mutation of the tyrosine kinase KIT at codon 816, expression of CD2 and/or CD25 by bone marrow mast cells, and a serum tryptase level \>20 ng/mL. CM is most common in children before puberty, most often presents as a rash or urticaria pigmentosa, and often resolves spontaneously. In adults, however, CM frequently progresses to SM. In contrast to CM, SM has a peak onset in adults, tends to be more aggressive, and can involve the skin as well as internal organs and bone marrow. Indolent SM accounts for 90% of the cases of SM and generally appears to have a good prognosis, although a wide variety of mediator-related symptoms are common, and these can be disabling or even life-threatening as in the case of hypotensive shock [@pone.0002266-Escribano1].

In the last 15 years, activating mutations have been found in codon 816 of the tyrosine kinase KIT in children and adults with mastocytosis [@pone.0002266-Feger1]. In particular, the D816V mutation has been found in most (\>80%) of patients with SM and therefore has been thought to promote the development of systemic and persistent disease. Furthermore, a recent study showed that expression of KIT with the D816V mutation causes mastocytosis in transgenic mice [@pone.0002266-Zappulla1]. For this reason, inhibitors of the KIT tyrosine kinase are being developed for the treatment of mastocytosis [@pone.0002266-Valent1].

Since 2001, to help understand the pathophysiology of mastocytosis and improve its treatment, AFIRMM (Association Française pour les Initiatives et la Recherche sur le Mastocyte et les Mastocytoses; <http://www.afirmm.com/>) has collected data on mastocytosis patients in France. To help physicians in the selection of appropriate treatments for mastocytosis, we performed a case-control study within the AFIRMM network to assess the patients\' perception of symptoms and the impact on their quality of life. On the basis of this information, we developed and validated a composite score that measures mastocytosis patients\' perception of disability (AFIRMM score). Using this score and an overall rating of self-perceived disability (OPA score), we examined the relationship between disability and the disease classification, the presence of the D816V KIT mutation, and the serum tryptase level. The AFIRMM score also allowed us to identify the symptoms that most contributed to the patients\' perception of disability.

Methods {#s2}
=======

The AFIRMM network {#s2a}
------------------

The AFIRMM network (<http://www.afirmm.com/>) was created in France in 1999 to collect data on patients suffering from mastocytosis, inform health care professionals and patients about mast cell disorders, support research to better understand mast cell disorders and thereby develop efficient symptomatic or curative treatments. The AFIRMM network currently includes more than 68 hospitals and clinical centers in France and Switzerland (principal investigators O.H. and O.L., Centre de référence de mastocytose, Hôpital Necker, Paris, France). Between 1999 and 2004, 1297 adult mastocytosis patients were identified in France by AFIRMM.

Study design and objectives {#s2b}
---------------------------

A case-control study was initiated in September 2004 by AFIRMM to examine patients\' disability due to mastocytosis. The objectives of the current cohort study were to (i) evaluate the patients\' perception of disability, (ii) establish and validate a composite score for disability, (iii) determine the most important symptoms causing the patients\' perception of disability, and (iv) correlate disability with mastocytosis classification and presence of the D816V KIT mutation and an elevated level of serum tryptase.

Patients and data collection {#s2c}
----------------------------

For the mastocytosis patient cohort, all adult (≥18 years) patients suffering mastocytosis identified by AFIRMM between 1999 and 2004 were eligible. In September 2004, AFIRMM sent questionnaires to 703 of the identified adult patients. The patients were asked to respond to (i) a unidimensional questionnaire on their overall perception of disability (overall patient assessment \[OPA\] questionnaire) and (ii) a multidimensional questionnaire containing 38 items on the patient\'s perception of disability from individual symptoms (AFIRMM questionnaire). Of the 703 patients that were sent questionnaires, 363 provided responses. At the same time or at a later date, the patients were also administered questionnaires to assess seven measurable parameters of disability (see "Measurable parameters of disability" below). All questionnaires were returned to and processed at the Service d\'Hématologie, Hôpital Necker (Paris, France). The case-control cohort included 90 members of the medical staff or their family members that were unaffected by and with no family member affected by mastocytosis. Data from questionnaires were collected according to French privacy laws, and all parts of the study were approved by the Ethics Committee of the Hôpital Necker, Paris, France.

Of the 363 patients that responded, 262 were part of an ongoing pathophysiological study started in November 2003 by AFIRMM. The patients selected and enrolled in the pathophysiological study included (i) patients suffering CM as documented by a skin biopsy and without mast cells in other tissues and (ii) patients suffering from SM as documented by mast cell infiltration in a bone marrow and/or another internal organ (i.e., liver or gastrointestinal tract) with or without skin involvement. In addition, all patients had to be affiliated with a social security regimen or covered by insurance. The patients in the pathophysiological study were recruited by investigators following a consultation where the investigator verbally informed the patients about the aims and conditions of the study. The patient received a patient information sheet, and written informed consent was obtained prior to the initiation of all study procedures. For these 262 patients, the following were collected or performed during a medical visit: demographics, information related to the diagnosis of mastocytosis, previous data on organ involvement and KIT characterization, WHO classification, physical examination (weight and vital signs), clinical examination (cutaneous and systemic symptoms), biological examination (hematology, biochemistry laboratory tests, and serum tryptase level), radiological examination, blood samples, skin biopsy, and bone marrow aspirate and/or biopsy. For these patients, a confirmation of diagnosis was given by a centralized review of all previous clinical and histopathological assessments. All procedures in the pathophysiological study were conducted according to guidelines for Good Clinical Practice [@pone.0002266-European1].

OPA Score {#s2d}
---------

The OPA score was determined from a unidimensional questionnaire, where the patients were asked, "How do you assess your disability in general (pain, general health status, impact on your life)? Grade 0, no disability; grade 1, light disability; grade 2, moderate disability; grade 3, severe disability; grade 4, intolerable disability."

AFIRMM Score {#s2e}
------------

A mutidimensional questionnaire (see Supporting Information) was designed by AFIRMM to collect information on patients\' perception of the severity of their symptoms and their impact on the quality of life. The questionnaire was designed on the basis of patient interviews between 1999 and 2004 to include the most commonly reported symptoms. There were a total of 38 specific symptoms in 12 categories (skin, allergy/flush/shock, gastrointestinal tract, rheumatology, asthenia, neurology/psychiatry, respiratory, urology, infection, hemorrhoidal inflammation, libido, and sweat). Each disability was assigned a grade between 0 and 4 (0, none; 1, light; 2, moderate; 3, severe; 4, intolerable). In addition, each disability grade was assigned a weighting of 1 to 5 to reflect the impact of the symptom\'s severity on the quality of life. The AFIRMM score was then calculated as follows:where n is the symptom number, *Grade* is the self-assessed severity of the symptom (0--4), and *Weight* = *Grade*+1. The resulting AFIRMM score can range from a minimum of 0 (no disability) to a maximum of 760 (most severe disability).

Measurable parameters of disability {#s2f}
-----------------------------------

AFIRMM selected seven measurable parameters to confirm disability in mastocytosis. This included four quantifiable disabilities: existence of life-threatening anaphylactoid episodes, number of flushing episodes per week, number of stools per day, and number of micturitions per day. In addition, three scores used to measure disability in other pathologies were assessed: a pruritus score (see Supporting Information), the Hamilton score for depression [@pone.0002266-Hedlung1], and the QLQ-C30 quality of life score [@pone.0002266-Aaronson1]. For these measures, the following were considered as indicating a disability: the existence of recurrent life-threatening anaphylactoid episodes, ≥7 episodes of flushing per week, ≥4 stools per day (diarrhea), ≥8 micturitions per day (pollakiuria), pruritus score ≥6, Hamilton score ≥10 (depression), QLQ-C30 score ≥60.

Detection of D816V KIT mutation {#s2g}
-------------------------------

For patients with CM, biopsies were collected from skin lesions, and for patients with SM, bone marrow aspirates were collected from the sternum or iliac crest. Bone marrow samples (3 mL) were collected in an EDTA tube (Becton Dickinson), and skin samples consisted of two to three punch biopsies of 3 to 4 mm from a cutaneous lesion collected in 1 mL of RNAlater (Qiagen). All biopsy samples were sent to Fabienne Palmerini, Institut Paoli Calmettes (Marseille, France) at room temperature. Samples arrived within 36 to 60 h. Immediately after reception, skin samples were frozen at −80°C, and prior to RNA extraction, they were homogenized using a Polytron T25 Ultra-turrax (Fisher Bioblock Scientific) in RLT buffer at room temperature. Marrow samples were mixed with NH~4~Cl lysis solution (8.3 g/L NH~4~Cl, 0.81 g/L NaHCO~3~, and 0.37 g/L EDTA) and incubated for 10 min at 4°C to lyse red blood cells. The marrow cells were then sedimented by centrifugation at 180× g for 10 min, washed with phosphate-buffered saline, pH 7.4 (Gibco), resuspended in RLT buffer (Qiagen), and stored at −80°C for later RNA extraction.

Total RNA was extracted from thawed samples using an RNeasy Mini Kit (Qiagen). Complementary DNA (cDNA) was synthesized in a total volume of 50 µl containing 200 ng of total RNA, random hexamers, and oligo dT using the StrataScript first-strand synthesis system (Stratagene) according to the manufacturer\'s instructions. Next, 2.5 µl of cDNA was amplified by PCR using HotStartTaq™ DNA polymerase (Qiagen) and primers 5′-GGATGACGAGTTGGCCCTAGA-3′ and 5′-GTAGAAACTTAGATCGACCGGCA-3′. Amplification was carried out for 40 cycles at 94°C for 30 s, 57°C for 30 s, and 72°C for 45 s. PCR products were purified with the Geneclean III kit (Qbiogene) and directly sequenced using a BigDye terminator kit v1.1 (Applied Biosystems) with primers 5′-TACCAGGTGGCAAAGGGCATG-3′ and 5′-CGACCGGCATTCCAGGATAG-3′ on an ABI Prism 3130 sequencer (Applied Biosystems). The entire coding region for *KIT* was sequenced, and the obtained sequences were analyzed with Seqscape software (Applied Biosystems).

The presence of the D816V mutation was also confirmed by restriction digestion analysis using *Bsm*A1 and *Ple*1, which detect the wild-type and mutated form of *KIT*, respectively. The cDNA was amplified by PCR as described above but using fluorescently labeled primers. The size of restriction digest fragments (201 bp for the *Bsm*A1 fragment and 179 and 187 for the *Ple*1 fragment) were then directly determined on a 16-capillary sequencer (ABI Prism 3130) by comparison with Genescan rox 500 markers (Applied Biosystems) using GeneMapper software (Applied Biosystems).

Measurement of serum tryptase {#s2h}
-----------------------------

The level of total tryptase (α-protryptase+β-tryptase) in serum samples was determined using a fluorescence enzyme-linked immunoassay (Unicap; Pharmacia) [@pone.0002266-Schwartz1]. The detection limit of this assay is 1 ng/mL, and in healthy controls, serum tryptase levels range between \<1 and 15 ng/mL, with a median of ∼5 ng/mL [@pone.0002266-Sperr1].

Statistical analyses {#s2i}
--------------------

Statistical analyses were performed using SAS version 9.1 (SAS Institute) and Excel (Microsoft Corp.). Quantitative variables were summarized using the following descriptive statistics: number of observed and missing data, mean, standard deviation, median, minimum and maximum. Absolute and relative frequency distributions were provided for qualitative variables. Qualitative variables were compared using a Chi-square test or Fisher exact test if at least one of the expected counts was less than five. Normally distributed quantitative variables were compared using Student\'s *t*-test. Distributed quantitative variables that did not have a normal distribution were compared using Wilcoxon\'s rank sum test. *P*\<0.05 was considered to indicate a statistically significant difference.

Results {#s3}
=======

Patient characteristics and data collected {#s3a}
------------------------------------------

During visits by mastocytosis patients between 1999 and 2004, we noticed that they tend to suffer from a very wide variety of common symptoms and that they often feel disabled by these symptoms. To gain a clearer picture of overall disability in mastocytosis and the type and severity of symptoms causing disability, we developed two questionnaires. The first was a unidimensional questionnaire asking the patients about their overall perception of disability (OPA questionnaire), and the second was a multidimensional questionnaire asking the patients about their perception of the severity of 38 symptoms in 12 categories (AFIRMM questionnaire; [Table S1](#pone.0002266.s001){ref-type="supplementary-material"}). In September 2004, we sent the questionnaires to 703 adult mastocytosis patients that had been identified by AFIRMM in France between 1999 and 2004. Responses to both questionnaires were obtained from 363 patients, 262 of whom were part of an ongoing pathophysiological study by AFIRMM. In addition, the questionnaires were administered to 90 control healthy subjects with no family members suffering from mastocytosis. The 363 patients included individuals with CM and both indolent and aggressive forms of SM, but none of the patients had mast cell leukemia (data not shown). Of the 262 patients in the pathophysiological study, 62 had their mastocytosis further validated by a central review of pathological samples and clinical data at Hôpital Necker ([Figure 1](#pone-0002266-g001){ref-type="fig"}).

![Control and patient groups in this study.\
A total of 363 patients and 90 controls answered AFIRMM and OPA questionnaires. Of the 363 patients, 262 were part of an ongoing pathophysiological study. Of these 262, 62 had their mastocytosis further validated by a careful centralized review of pathological samples and clinical data at Hôpital Necker.](pone.0002266.g001){#pone-0002266-g001}

OPA Score {#s3b}
---------

First, we compared the OPA scores between the patient and control cohorts ([Table S2](#pone.0002266.s002){ref-type="supplementary-material"}). The OPA score was based on patients\' response to a single question: "How do you assess your disability in general (pain, overall health status, impact on your life)?" Of the 363 patients in the patient cohort, 254 (70%) declared that they suffered from a disability, including 62 (17%) who said it was severe or intolerable, whereas only 8 of 90 (9%) of the control patients said they had a disability (*P*\<0.001 by Chi square test). Also, in contrast to the patients, none of the controls reported having a severe or intolerable disability.

We further examined the OPA score in the 262 patients in the pathophysiological study and the 62 patients whose mastocytosis was confirmed by a central review of pathological and clinical data at Hôpital Necker. Again, we found a significant difference in the fraction reporting a disability between the patients and controls. Thus, regardless of the level of validation, mastocytosis patients feel disabled by their disease.

We next examined whether the OPA score was different between patients with CM and SM ([Table 1](#pone-0002266-t001){ref-type="table"}). Of the 262 patients for whom pathophysiological data was available, the WHO classification was known for 115. Of these, 33 (29%) were diagnosed with CM and the remaining 82 (71%) with SM. For patients diagnosed with CM, 64% (21/33) declared that they suffered from a disability, including 15% (5/33) who said that it was severe or intolerable, and of those with SM, 82% (67/82) reported having a disability and 28% (23/82) declared that it was severe or intolerable. The proportion declaring a disability was slightly different (*P* = 0.0386 by Chi square test) between patients with CM and SM; however, the difference was not significant when the analysis was limited to patients whose mastocytosis was further validated by a central review of all pathological and clinical data. These results indicate that CM and SM patients feel equally disabled by their disease.

10.1371/journal.pone.0002266.t001

###### OPA scores.

![](pone.0002266.t001){#pone-0002266-t001-1}

  *Variable*                                Group      *n*   Perceived Handicap                                             
  -------------------------------------- ------------ ----- -------------------- ----------- ---------- ---------- -------- ---------------------------------------------
  *All cases*                                                                                                               
  Controls                                             90         82 (91%)         5 (6%)      3 (3%)     0 (0%)    0 (0%)  
  All patients                                         363       109 (30%)        107 (29%)   85 (23%)   59 (16%)   3 (1%)   *\<0.0001* [a](#nt101){ref-type="table-fn"}
  Patients in pathophysiological study                 262        68 (26%)        75 (29%)    68 (26%)   49 (19%)   2 (1%)   *\<0.0001* [a](#nt101){ref-type="table-fn"}
  Patients confirmed by central review                 62         8 (13%)         21 (34%)    16 (26%)   16 (26%)   1 (2%)   *\<0.0001* [a](#nt101){ref-type="table-fn"}
  *Clinical form*                                                                                                           
  Patients in pathophysiological study        CM       33         12 (36%)         7 (21%)    9 (27%)    5 (15%)    0 (0%)    *0.0386* [b](#nt102){ref-type="table-fn"}
                                              SM       82         15 (18%)        28 (34%)    16 (20%)   22 (27%)   1 (1%)  
  Patients confirmed by central review        CM       13         2 (15%)          3 (23%)    6 (46%)    2 (15%)    0 (0%)      0.61[c](#nt103){ref-type="table-fn"}
                                              SM       44          4 (9%)         15 (34%)    10 (23%)   14 (32%)   1 (2%)  
  *KIT status*                                                                                                              
  Patients in pathophysiological study      D816V      72         17 (24%)        19 (26%)    19 (26%)   16 (22%)   1 (1%)      0.64[d](#nt104){ref-type="table-fn"}
                                           No D816V    162        43 (27%)        52 (32%)    43 (27%)   23 (14%)   1 (1%)  
  Patients confirmed by central review      D816V      16         2 (13%)          3 (19%)    6 (38%)    5 (31%)    0 (0%)      1.00[e](#nt105){ref-type="table-fn"}
                                           No D816V    40         6 (15%)         16 (40%)    10 (25%)   7 (18%)    1 (3%)  
  *Serum tryptase*                                                                                                          
  Patients in pathophysiological study    \<20 ng/mL   53         12 (23%)        16 (30%)    13 (25%)   11 (21%)   1 (2%)      0.52[f](#nt106){ref-type="table-fn"}
                                          ≥20 ng/mL    87         24 (28%)        24 (28%)    19 (22%)   20 (23%)   0 (0%)  
  Patients confirmed by central review    \<20 ng/mL   20         2 (10%)          7 (35%)    6 (30%)    4 (20%)    1 (5%)      0.70[g](#nt107){ref-type="table-fn"}
                                          ≥20 ng/mL    34         6 (18%)         12 (35%)    7 (21%)    9 (26%)    0 (0%)  

*P*-value calculated by Chi-square test for patients reporting a handicap vs. control.

*P*-value calculated between CM and SM by Chi-square test.

*P*-value calculated between CM and SM by Fisher\'s exact test.

*P*-value calculated between presence and absence of D816V KIT mutation by Chi-square test.

*P*-value calculated between presence and absence of D816V KIT mutation by Fisher\'s exact test.

*P*-value calculated between serum tryptase ≤20 and \>20 ng/mL by Chi-square test.

*P*-value calculated between serum tryptase ≤20 and \>20 ng/mL by Fisher exact test. Statistically significant differences (\<0.05) are shown in italics

Because the KIT D816V mutation is suggested to correlate with the occurrence of SM in adult patients and to contribute to its progression [@pone.0002266-Valent1], [@pone.0002266-Akin1], we next examined whether it correlates with the OPA score ([Table 1](#pone-0002266-t001){ref-type="table"}). The KIT status was known for 234 patients and the serum tryptase level for 140 of the patients. There was no difference in the OPA score according to the presence of the D816V KIT mutation for all patients whose classification was known or for patients whose mastocytosis was confirmed by a central review of pathological and clinical data. Collectively, these results indicate that patients\' overall perception of disability is unrelated to the presence of the D816V mutation.

We also examined the correlation between the OPA score and the total serum tryptase level because a level ≥20 ng/mL is used as a criterion for a diagnosis SM [@pone.0002266-Valent2], [@pone.0002266-Schwartz2], [@pone.0002266-Akin2]. In addition, recent studies show that the serum tryptase level positively correlates with the severity category of SM [@pone.0002266-Proelss1], [@pone.0002266-Rogers1]. As shown in [Table 1](#pone-0002266-t001){ref-type="table"}, there was no significant difference between the OPA score according to the presence of an elevated (≥20 ng/mL) serum tryptase level. This was also found when the analysis was limited to patients whose mastocytosis was validated by a central review of pathological and clinical data. These findings indicate that the patients\' overall perception of disability is unrelated to whether they have an elevated serum tryptase level.

AFIRMM score {#s3c}
------------

To allow analysis of the severity of the individual symptoms and their contribution to the patients\' perception of disability in mastocytosis, we designed a questionnaire that assesses the severity or self-perceived severity of 38 distinct symptoms in 12 different categories. Each symptom was given a grade from 0 to 4, and each grade was assigned a weight from 1 to 5 to reflect the impact of each level of disability on the quality of life. This information was used to calculate a composite score (AFIRMM score) that ranged from 0 to 760 (from least to most severe).

As shown in [Table 2](#pone-0002266-t002){ref-type="table"}, the mean AFIRMM score was significantly higher for the patient cohort than for the control cohort (mean±standard deviation, 117±78 \[n = 363\] vs. 29±27 \[n = 90\]; *P*\<0.0001). This result was also found when the analysis was limited to the 262 patients who were part of the pathophysiological study and to the subsets of patients whose mastocytosis was validated by a central review of pathological and clinical data.

10.1371/journal.pone.0002266.t002

###### AFIRMM scores.

![](pone.0002266.t002){#pone-0002266-t002-2}

  *Variable*                                Group      *n*    Mean±SD     Median    Min--Max                      *P*-value
  -------------------------------------- ------------ ----- ------------ -------- ------------- ---------------------------------------------
  *All cases*                                                                                   
  Controls                                             90      29±27        21       0--150                          --
  All patients                                         363     117±84      104                   *\<0.0001* [a](#nt108){ref-type="table-fn"}
  Patients in pathophysiological study                 262   124.8±79.9    111     6.0--410.0    *\<0.0001* [a](#nt108){ref-type="table-fn"}
  Patients confirmed by central review                 62    144.5±83.3    133     22.0--410.0   *\<0.0001* [a](#nt108){ref-type="table-fn"}
  *Clinical form*                                                                               
  Patients in pathophysiological study        CM       33      103±75       84       20--408      *0.0225* [b](#nt109){ref-type="table-fn"}
                                              SM       82      135±82      124       6--410     
  Patients confirmed by central review        CM       13    145.7±95.0    128     46.0--408.0      0.54[b](#nt109){ref-type="table-fn"}
                                              SM       44    152.9±79.0    144     50.0--410.0  
  *KIT status*                                                                                  
  Patients in pathophysiological study      D816V      72      129±79      119       6--358         0.29[c](#nt110){ref-type="table-fn"}
                                           No D816V    162     119±79      104       6--410     
  Patients confirmed by central review      D816V      16    136.0±65.2    130     28.0--240.0      0.96[c](#nt110){ref-type="table-fn"}
                                           No D816V    40    145.5±90.4    129     22.0--410.0  
  *Serum tryptase*                                                                              
  Patients in pathophysiological study    \<20 ng/mL   53      117±75      116       26--410        0.86[d](#nt111){ref-type="table-fn"}
                                          ≥20 ng/mL    87      121±82      102       6--408     
  Patients confirmed by central review    \<20 ng/mL   20    139.6±91.1    121     28.0--410.0      0.99[d](#nt111){ref-type="table-fn"}
                                          ≥20 ng/mL    34    137.6±83.5    128     22.0--408.0  

*P*-value for patient group vs. control cohort by Wilcoxson test.

*P*-value for CM vs. SM by Wilcoxson test.

*P*-values for D816V vs. no D816V by Wilcoxson test.

*P*-value for serum tryptase ≤20 ng/mL vs. \>20 ng/mL by Wilcoxson test. Statistically significant differences (\<0.05) are shown in italics.

We found a slight difference in the AFIRMM score between patients with CM and SM (mean±standard deviation, 103±75 \[n = 33\] vs. 135±82 \[n = 90\]; *P* = 0.0225), but the difference was not significant when the analysis was limited to patients whose mastocytosis was validated by a central review of pathological and clinical data ([Table 2](#pone-0002266-t002){ref-type="table"}). There was also not a significant difference between the AFIRMM score according to the presence or absence of the KIT D816V mutation or a serum tryptase level \>20 ng/mL, regardless of the subgroup of patients analyzed. These results agree with the findings from the OPA score that mastocytosis patients feel disabled by their symptoms regardless of whether they have CM or SM, that the overall extent of disability does not differ significantly between these two main types of mastocytosis, and that overall disability is unrelated to the presence of the presence of the D816V mutation or an elevated serum tryptase level. Thus, the AFIRMM score appears to reflect the patients\' overall perception of disability from mastocytosis.

We next examined the results on a symptom-by-symptom basis. We found that for the vast majority (32/38) of symptoms, there was a statistically significant difference in the proportion of patients and controls reporting some disability (grades 1--4) ([Table 3](#pone-0002266-t003){ref-type="table"}). According to the score (*Grade*×*Weight*), the 10 symptoms most contributing to the patients\' perception of disability were (in decreasing order) psychological impact of cutaneous problems, asthenia (fatigue), pruritus, food allergy/intolerance, erythemateous crisis, muscle and joint pain/cramps, pollakiuria, drug allergy, aerophagia/eruction, and dyspnea/bronchoreactivity. When the analysis was limited to patients whose mastocytosis was validated by a central review, there was some variability in whether certain symptoms (i.e., aerophagia/eruction, ocular discomfort, erectile function/ability to make love, and dysuria) were statistically significant or not (data not shown); however, except for dysuria, when only severe or intolerable disabilities (grades 3 or 4) were considered, all of these were found to be significantly more common in patients than in controls ([Table 3](#pone-0002266-t003){ref-type="table"}), suggesting that they represent disabling symptoms of mastocytosis.

10.1371/journal.pone.0002266.t003

###### Disability by symptom: patients vs. controls.

![](pone.0002266.t003){#pone-0002266-t003-3}

  Symptom                                              Rank[a](#nt112){ref-type="table-fn"}   Controls   Patients   *P*-value[b](#nt113){ref-type="table-fn"}                                             
  --------------------------------------------------- -------------------------------------- ---------- ---------- ------------------------------------------- ----- ----------- ----------- ------------ -------------------------------------------
  Psychological impact                                                  1                        90      9 (10%)                     1 (1%)                     363   261 (72%)   120 (33%)   *\<0.0001*                  *\<0.0001*
  Asthenia                                                              2                        90      34 (38%)                    3 (3%)                     362   296 (82%)   102 (28%)   *\<0.0001*                  *\<0.0001*
  Pruritus                                                              3                        90      25 (28%)                    3 (3%)                     363   299 (82%)   82 (23%)    *\<0.0001*                  *\<0.0001*
  Food allergy/intolerance                                              4                        90      9 (10%)                     0 (0%)                     363   222 (61%)   97 (27%)    *\<0.0001*                  *\<0.0001*
  Erythemateous crisis                                                  5                        90      17 (19%)                    1 (1%)                     363   293 (81%)   69 (19%)    *\<0.0001*                  *\<0.0001*
  Muscle and joint pain, cramps                                         6                        90      36 (40%)                    3 (3%)                     363   276 (76%)   71 (20%)    *\<0.0001*                   *0.0002*
  Pollakiuria                                                           7                        90      58 (64%)                    6 (7%)                     362   263 (73%)   64 (18%)       0.12                      *0.0098*
  Drug allergy                                                          8                        90      16 (18%)                    0 (0%)                     363   205 (56%)   70 (19%)    *\<0.0001*                  *\<0.0001*
  Aerophagia/eructation                                                 9                        90      43 (48%)                    1 (1%)                     363   229 (63%)   62 (17%)     *0.0080*                   *\<0.0001*
  Dyspnea/bronchoreactivity                                             10                       90      15 (17%)                    3 (3%)                     362   154 (43%)   94 (26%)    *\<0.0001*                  *\<0.0001*
  Headache                                                              11                       90      34 (38%)                    4 (4%)                     362   250 (69%)   48 (13%)    *\<0.0001*                   *0.0190*
  Bone pain                                                             12                       90      16 (18%)                    0 (0%)                     363   196 (54%)   65 (18%)    *\<0.0001*                  *\<0.0001*
  Reduced sexual relations                                              13                       90      11 (12%)                    4 (4%)                     362   132 (36%)   65 (18%)    *\<0.0001*                   *0.0014*
  Epigastric pain                                                       14                       90      35 (39%)                    2 (2%)                     362   249 (69%)   40 (11%)    *\<0.0001*                   *0.0100*
  Ocular discomfort                                                     15                       90      43 (48%)                    1 (1%)                     363   219 (60%)   55 (15%)     *0.0309*                    *0.0003*
  Memory loss                                                           16                       90      32 (36%)                    0 (0%)                     362   240 (66%)    34 (9%)    *\<0.0001*                   *0.0025*
  Tinnitus                                                              17                       90      29 (32%)                    1 (1%)                     363   166 (46%)   47 (13%)     *0.0205*                    *0.0011*
  Pseudo-occlusive syndrome                                             18                       90      20 (22%)                    0 (0%)                     363   199 (55%)   36 (10%)    *\<0.0001*                   *0.0018*
  Infections (bronchitis, rhinitis, conjunctivitis)                     19                       90      25 (28%)                    2 (2%)                     363   182 (50%)   38 (10%)     *0.0001*                    *0.0136*
  Olfactive intolerance                                                 20                       90      33 (37%)                    1 (1%)                     363   188 (52%)   39 (11%)     *0.0102*                    *0.0039*
  Social interaction                                                    21                       90      9 (10%)                     0 (0%)                     362   200 (55%)    26 (7%)    *\<0.0001*                   *0.0088*
  Depression                                                            22                       90      19 (21%)                    0 (0%)                     362   205 (57%)    22 (6%)    *\<0.0001*   *0.0114* [e](#nt116){ref-type="table-fn"}
  Mobility                                                              23                       90       6 (7%)                     0 (0%)                     363   153 (42%)   35 (10%)    *\<0.0001*                   *0.0022*
  Anaphylactic shock                                                    24                       90      12 (13%)                    0 (0%)                     363   160 (44%)    30 (8%)    *\<0.0001*                   *0.0048*
  Sweating                                                              25                       90      19 (21%)                    2 (2%)                     363   169 (47%)    30 (8%)    *\<0.0001*                   *0.0452*
  Stomatitis                                                            26                       90      28 (31%)                    1 (1%)                     363   145 (40%)    34 (9%)       0.12                      *0.0086*
  Flush                                                                 27                       90      9 (10%)                     0 (0%)                     363   190 (52%)    23 (6%)    *\<0.0001*   *0.0123* [e](#nt116){ref-type="table-fn"}
  Performance status                                                    28                       90      11 (12%)                    1 (1%)                     362   187 (52%)    25 (7%)    *\<0.0001*                   *0.0346*
  Hemorrhoids                                                           29                       90      19 (21%)                    1 (1%)                     363   156 (43%)    23 (6%)     *0.0001*      0.06[e](#nt116){ref-type="table-fn"}
  Cough                                                                 30                       90      22 (24%)                    0 (0%)                     362   171 (47%)    9 (2%)     *\<0.0001*     0.22[e](#nt116){ref-type="table-fn"}
  Ear/nose/throat inflammation                                          31                       90      13 (14%)                    0 (0%)                     362   120 (33%)    20 (6%)     *0.0005*    *0.0188* [e](#nt116){ref-type="table-fn"}
  Erectile function/ability to make love                                32                       90      10 (11%)                    2 (2%)                     362   71 (20%)     34 (9%)       0.06                      *0.0246*
  Nausea, vomiting                                                      33                       90      20 (22%)                    0 (0%)                     363   179 (49%)    12 (3%)    *\<0.0001*     0.14[e](#nt116){ref-type="table-fn"}
  Diarrhea                                                              34                       90       6 (7%)                     0 (0%)                     363   127 (35%)    10 (3%)    *\<0.0001*     0.22[e](#nt116){ref-type="table-fn"}
  Warts                                                                 35                       90      14 (16%)                    1 (1%)                     363   82 (23%)     10 (3%)       0.14        0.70[e](#nt116){ref-type="table-fn"}
  Pain                                                                  36                       90       4 (4%)                     0 (0%)                     362   71 (20%)     7 (2%)      *0.0005*      0.35[e](#nt116){ref-type="table-fn"}
  Folliculitis                                                          37                       90       7 (8%)                     1 (1%)                     362   56 (15%)     6 (2%)        0.06        1.00[e](#nt116){ref-type="table-fn"}
  Dysuria                                                               38                       90       6 (7%)                     0 (0%)                     362   51 (14%)     3 (1%)        0.06        1.00[e](#nt116){ref-type="table-fn"}

Symptoms were ranked according to the average score (grade×weight).

*P*-values were calculated between controls and patients by Chi square test except where noted.

Grades 1--4.

Grades 3 and 4 only.

*P*-value calculated by Fisher\'s exact test. Statistically significant differences (\<0.05) are shown in italics.

For the vast majority of individual symptoms, perceived disability did not differ between CM and SM patients ([Table 4](#pone-0002266-t004){ref-type="table"}). Reduced erections or ability to make love was the only exception: a disability was reported by more SM than CM patients (31% vs. 3%; *P* = 0.0013), and a substantial portion (15%) of SM patients but none of the CM patients (*P* = 0.0176) reported this symptom as severe or intolerable. Also, slightly more SM patients reported disability from pseudo-occlusive syndrome (57% vs. 33%; *P* = 0.0200) and muscle/joint pain and cramps (88% vs. 70%; *P* = 0.0205), although the frequencies were not significantly different when only severe or intolerable disabilities (grades 3 or 4) were considered.

10.1371/journal.pone.0002266.t004

###### Disability by symptom: comparison by classification (CM vs. SM).

![](pone.0002266.t004){#pone-0002266-t004-4}

  Symptom                                              CM      SM      *P*-value[a](#nt117){ref-type="table-fn"}                                        
  --------------------------------------------------- ---- ---------- ------------------------------------------- ---- ---------- ---------- ---------- -------------------------------------------
  Psychological impact                                 33   27 (82%)                   12 (36%)                    82   61 (74%)   33 (40%)     0.40                       0.70
  Asthenia                                             33   25 (76%)                    9 (27%)                    81   68 (84%)   29 (36%)     0.31                       0.38
  Pruritus                                             33   26 (79%)                    6 (18%)                    82   69 (84%)   23 (28%)     0.49                       0.27
  Food allergy/intolerance                             33   19 (58%)                    7 (21%)                    82   52 (63%)   19 (23%)     0.56                       0.82
  Erythemateous crisis                                 33   26 (79%)                    6 (18%)                    82   70 (85%)   20 (24%)     0.39                       0.47
  Muscle and joint pain, cramps                        33   23 (70%)                    7 (21%)                    82   72 (88%)   23 (28%)   *0.0205*                     0.45
  Pollakiuria                                          33   21 (64%)                    5 (15%)                    81   60 (74%)   20 (25%)     0.27                       0.26
  Drug allergy                                         33   19 (58%)                    3 (9%)                     82   48 (59%)   17 (21%)     0.92                       0.14
  Aerophagia/eructation                                33   19 (58%)                    6 (18%)                    82   52 (63%)   13 (16%)     0.56                       0.76
  Dyspnea/bronchoreactivity                            33   14 (42%)                    8 (24%)                    81   37 (46%)   24 (30%)     0.75                       0.56
  Headache                                             33   24 (73%)                    5 (15%)                    81   58 (72%)   9 (11%)      0.90       0.54[d](#nt120){ref-type="table-fn"}
  Bone pain                                            33   18 (55%)                    7 (21%)                    82   58 (71%)   17 (21%)     0.10                       0.95
  Reduced sexual relations                             33   7 (21%)                     3 (9%)                     82   41 (50%)   20 (24%)   *0.0046*                     0.06
  Epigastric pain                                      33   22 (67%)                    2 (6%)                     82   50 (61%)   8 (10%)      0.57       0.72[d](#nt120){ref-type="table-fn"}
  Ocular discomfort                                    33   20 (61%)                    5 (15%)                    82   47 (57%)   10 (12%)     0.75       0.76[d](#nt120){ref-type="table-fn"}
  Memory loss                                          33   21 (64%)                    1 (3%)                     81   58 (72%)   15 (19%)     0.40     *0.0366* [d](#nt120){ref-type="table-fn"}
  Tinnitus                                             33   16 (48%)                    5 (15%)                    82   39 (48%)   15 (18%)     0.93                       0.69
  Pseudo-occlusive syndrome                            33   11 (33%)                    1 (3%)                     82   47 (57%)   9 (11%)    *0.0200*     0.28[d](#nt120){ref-type="table-fn"}
  Infections (bronchitis, rhinitis, conjunctivitis)    33   14 (42%)                    2 (6%)                     82   42 (51%)   10 (12%)     0.39       0.50[d](#nt120){ref-type="table-fn"}
  Olfactive intolerance                                33   17 (52%)                    1 (3%)                     82   48 (59%)   8 (10%)      0.49       0.44[d](#nt120){ref-type="table-fn"}
  Social interaction                                   33   14 (42%)                    1 (3%)                     81   46 (57%)    7 (9%)      0.16       0.43[d](#nt120){ref-type="table-fn"}
  Depression                                           33   15 (45%)                    3 (9%)                     81   51 (63%)    6 (7%)      0.09       0.72[d](#nt120){ref-type="table-fn"}
  Mobility                                             33   14 (42%)                    2 (6%)                     82   47 (57%)   13 (16%)     0.15       0.23[d](#nt120){ref-type="table-fn"}
  Anaphylactic shock                                   33   16 (48%)                    3 (9%)                     82   39 (48%)   8 (10%)      0.93       1.00[d](#nt120){ref-type="table-fn"}
  Sweat                                                33   17 (52%)                    3 (9%)                     82   34 (41%)   8 (10%)      0.33       1.00[d](#nt120){ref-type="table-fn"}
  Stomatitis                                           33   11 (33%)                    3 (9%)                     82   33 (40%)   10 (12%)     0.49       0.75[d](#nt120){ref-type="table-fn"}
  Flush                                                33   23 (70%)                    2 (6%)                     82   47 (57%)    7 (9%)      0.22       1.00[d](#nt120){ref-type="table-fn"}
  Performance status                                   33   16 (48%)                    3 (9%)                     81   53 (65%)   11 (14%)     0.09       0.75[d](#nt120){ref-type="table-fn"}
  Hemorrhoids                                          33   10 (30%)                    1 (3%)                     82   40 (49%)   10 (12%)     0.07       0.17[d](#nt120){ref-type="table-fn"}
  Cough                                                33   15 (45%)                    0 (0%)                     81   43 (53%)    2 (2%)      0.46       1.00[d](#nt120){ref-type="table-fn"}
  Ear/nose/throat inflammation                         33   11 (33%)                    1 (3%)                     81   24 (30%)    5 (6%)      0.70       0.67[d](#nt120){ref-type="table-fn"}
  Erectile function/ability to make love               33    1 (3%)                     0 (0%)                     81   25 (31%)   12 (15%)   *0.0013*                   *0.0176*
  Nausea, vomiting                                     33   15 (45%)                    2 (6%)                     82   48 (59%)    3 (4%)      0.20       0.62[d](#nt120){ref-type="table-fn"}
  Diarrhea                                             33   11 (33%)                    0 (0%)                     82   29 (35%)    6 (7%)      0.84       0.18[d](#nt120){ref-type="table-fn"}
  Warts                                                33   6 (18%)                     0 (0%)                     82   16 (20%)    4 (5%)      0.87       0.32[d](#nt120){ref-type="table-fn"}
  Pain                                                 33   5 (15%)                     0 (0%)                     81   17 (21%)    3 (4%)      0.47       0.56[d](#nt120){ref-type="table-fn"}
  Folliculitis                                         33   5 (15%)                     1 (3%)                     81   10 (12%)    1 (1%)      0.76       0.50[d](#nt120){ref-type="table-fn"}
  Dysuria                                              33   4 (12%)                     0 (0%)                     81   15 (19%)    1 (1%)      0.41       1.00[d](#nt120){ref-type="table-fn"}

*P*-values were calculated between CM and SM by Chi square test except where noted.

Grades 1--4.

Grades 3 and 4 only.

*P*-value calculated by Fisher\'s exact test. Symptoms are listed in the same order as in [Table 4](#pone-0002266-t004){ref-type="table"}. Statistically significant differences (\<0.05) are shown in italics.

Comparison of the extent of disability from the individual symptoms according to the presence or absence of the D816V mutation also revealed few substantial differences ([Table 5](#pone-0002266-t005){ref-type="table"}). Three of the 38 symptoms (erythemateous crisis, psychological impact, and pseudo-occlusive syndrome) were more common in those with the D816V mutation, and five symptoms (olfactive intolerance, gastric pain, mobility, ocular disorders, and stomatitis) were more common in those without the mutation. Of these, only the psychological impact of cutaneous problems was significantly different (more common in those with the D816V mutation) when only severe or intolerable disabilities were considered.

10.1371/journal.pone.0002266.t005

###### Disability by symptom: comparison by the presence or absence of D816V KIT mutation.
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  Symptom                                              No D816V    D816V     *P*-value[a](#nt121){ref-type="table-fn"}                                            
  --------------------------------------------------- ---------- ---------- ------------------------------------------- ----- ----------- ---------- ------------ --------------------------------------
  Psychological impact                                    72      41 (57%)                   18 (25%)                    162   133 (82%)   71 (44%)   *\<0.0001*                 *0.0062*
  Asthenia                                                72      62 (86%)                   26 (36%)                    161   133 (83%)   45 (28%)      0.50                      0.21
  Pruritus                                                72      64 (89%)                   18 (25%)                    162   132 (81%)   42 (26%)      0.16                      0.88
  Food allergy/intolerance                                72      46 (64%)                   17 (24%)                    162   95 (59%)    42 (26%)      0.45                      0.71
  Erythemateous crisis                                    72      52 (72%)                   11 (15%)                    162   140 (86%)   35 (22%)    *0.0090*                    0.26
  Muscle and joint pain, cramps                           72      55 (76%)                   21 (29%)                    162   127 (78%)   28 (17%)      0.73                    *0.0392*
  Pollakiuria                                             72      47 (65%)                   13 (18%)                    161   120 (75%)   32 (20%)      0.15                      0.75
  Drug allergy                                            72      43 (60%)                   15 (21%)                    162   92 (57%)    31 (19%)      0.68                      0.76
  Aerophagia/eructation                                   72      50 (69%)                   16 (22%)                    162   94 (58%)    29 (18%)      0.10                      0.44
  Dyspnea/bronchoreactivity                               72      34 (47%)                   23 (32%)                    161   68 (42%)    44 (27%)      0.48                      0.47
  Headache                                                72      53 (74%)                   11 (15%)                    161   108 (67%)   21 (13%)      0.32                      0.65
  Bone pain                                               72      41 (57%)                   14 (19%)                    162   90 (56%)    27 (17%)      0.84                      0.61
  Reduced sexual relations                                72      29 (40%)                   16 (22%)                    161   62 (39%)    31 (19%)      0.80                      0.60
  Epigastric pain                                         72      53 (74%)                   12 (17%)                    162   97 (60%)    15 (9%)     *0.0432*                    0.10
  Ocular discomfort                                       72      52 (72%)                   12 (17%)                    162   89 (55%)    27 (17%)    *0.0126*                    1.00
  Memory loss                                             72      47 (65%)                    6 (8%)                     161   107 (66%)   19 (12%)      0.86                      0.43
  Tinnitus                                                72      33 (46%)                    9 (13%)                    162   80 (49%)    22 (14%)      0.62                      0.82
  Pseudo-occlusive syndrome                               72      32 (44%)                    7 (10%)                    162   95 (59%)    16 (10%)    *0.0442*                    0.97
  Infections (bronchitis, rhinitis, conjunctivitis)       72      39 (54%)                    8 (11%)                    162   75 (46%)    18 (11%)      0.27                      1.00
  Olfactive intolerance                                   72      45 (63%)                   10 (14%)                    162   75 (46%)    12 (7%)     *0.0221*                    0.12
  Social interaction                                      72      41 (57%)                    8 (11%)                    161   87 (54%)    11 (7%)       0.68                      0.27
  Depression                                              72      41 (57%)                    6 (8%)                     161   99 (61%)    14 (9%)       0.51                      0.93
  Mobility                                                72      40 (56%)                    9 (13%)                    162   67 (41%)    15 (9%)     *0.0442*                    0.45
  Anaphylactic shock                                      72      40 (56%)                    7 (10%)                    162   72 (44%)    14 (9%)       0.12                      0.79
  Sweat                                                   72      39 (54%)                   10 (14%)                    162   74 (46%)    13 (8%)       0.23                      0.16
  Stomatitis                                              72      36 (50%)                   10 (14%)                    162   58 (36%)    13 (8%)     *0.0409*                    0.16
  Flush                                                   72      41 (57%)                    4 (6%)                     162   97 (60%)    11 (7%)       0.67      1.00[d](#nt124){ref-type="table-fn"}
  Performance status                                      72      44 (61%)                    6 (8%)                     161   83 (52%)    13 (8%)       0.18                      0.95
  Hemorrhoids                                             72      31 (43%)                    5 (7%)                     162   76 (47%)    12 (7%)       0.58                      0.90
  Cough                                                   72      40 (56%)                    2 (3%)                     161   68 (42%)     6 (4%)       0.06      1.00[d](#nt124){ref-type="table-fn"}
  Ear/nose/throat inflammation                            72      26 (36%)                    5 (7%)                     161   53 (33%)     6 (4%)       0.63      0.32[d](#nt124){ref-type="table-fn"}
  Erectile function/ability to make love                  72      16 (22%)                    7 (10%)                    161   34 (21%)    16 (10%)      0.85                      0.96
  Nausea, vomiting                                        72      43 (60%)                    4 (6%)                     162   79 (49%)     7 (4%)       0.12      0.74[d](#nt124){ref-type="table-fn"}
  Diarrhea                                                72      33 (46%)                    2 (3%)                     162   53 (33%)     5 (3%)       0.05      1.00[d](#nt124){ref-type="table-fn"}
  Warts                                                   72      19 (26%)                    2 (3%)                     162   31 (19%)     5 (3%)       0.21      1.00[d](#nt124){ref-type="table-fn"}
  Pain                                                    72      17 (24%)                    2 (3%)                     161   28 (17%)     3 (2%)       0.27      0.65[d](#nt124){ref-type="table-fn"}
  Folliculitis                                            72      12 (17%)                    1 (1%)                     161   22 (14%)     3 (2%)       0.55      1.00[d](#nt124){ref-type="table-fn"}
  Dysuria                                                 72      9 (13%)                     1 (1%)                     161   22 (14%)     0 (0%)       0.81      0.31[d](#nt124){ref-type="table-fn"}

*P*-value calculated between CM and SM by Chi square test except where noted.

Grades 1--4.

Grades 3 and 4 only.

*P*-value calculated by Fisher\'s exact test. Symptoms are listed in the same order as in [Table 4](#pone-0002266-t004){ref-type="table"}. Statistically significant differences (\<0.05) are shown in italics.

The extent of disability for the individual symptoms did not appear to differ according to the presence or absence of an elevated (\>20 ng/mL) serum tryptase level ([Table 6](#pone-0002266-t006){ref-type="table"}). Ocular discomfort was somewhat more common in patients with a serum tryptase level ≤20 ng/mL, but this difference was not observed when only severe or intolerable disabilities were considered.

10.1371/journal.pone.0002266.t006

###### Disability by symptom: comparison by serum tryptase level.

![](pone.0002266.t006){#pone-0002266-t006-6}

  Symptom                                              ≤20 ng/ml   \>20 ng/ml   *P*-value[a](#nt125){ref-type="table-fn"}                                        
  --------------------------------------------------- ----------- ------------ ------------------------------------------- ---- ---------- ---------- ---------- -------------------------------------------
  Psychological impact                                    53        34 (64%)                    13 (25%)                    87   67 (77%)   41 (47%)     0.10                     *0.0077*
  Asthenia                                                53        46 (87%)                    20 (38%)                    86   67 (78%)   27 (31%)     0.19                       0.44
  Pruritus                                                53        42 (79%)                    13 (25%)                    87   71 (82%)   19 (22%)     0.73                       0.71
  Food allergy/intolerance                                53        32 (60%)                    12 (23%)                    87   52 (60%)   18 (21%)     0.94                       0.78
  Erythemateous crisis                                    53        40 (75%)                     8 (15%)                    87   71 (82%)   20 (23%)     0.38                       0.26
  Muscle and joint pain, cramps                           53        41 (77%)                    13 (25%)                    87   68 (78%)   19 (22%)     0.91                       0.71
  Pollakiuria                                             53        35 (66%)                    10 (19%)                    86   60 (70%)   17 (20%)     0.65                       0.90
  Drug allergy                                            53        33 (62%)                     9 (17%)                    87   47 (54%)   19 (22%)     0.34                       0.49
  Aerophagia/eructation                                   53        30 (57%)                     4 (8%)                     87   51 (59%)   16 (18%)     0.81                       0.08
  Dyspnea/bronchoreactivity                               53        23 (43%)                    16 (30%)                    86   38 (44%)   27 (31%)     0.93                       0.88
  Headache                                                53        35 (66%)                     7 (13%)                    86   58 (67%)    8 (9%)      0.86                       0.47
  Bone pain                                               53        31 (58%)                    10 (19%)                    87   56 (64%)   19 (22%)     0.49                       0.67
  Reduced sexual relations                                53        20 (38%)                     7 (13%)                    87   35 (40%)   20 (23%)     0.77                       0.15
  Epigastric pain                                         53        31 (58%)                     2 (4%)                     87   54 (62%)   11 (13%)     0.67       0.13[d](#nt128){ref-type="table-fn"}
  Ocular discomfort                                       53        37 (70%)                     8 (15%)                    87   42 (48%)   11 (13%)   *0.0127*                     0.68
  Memory loss                                             53        36 (68%)                     6 (11%)                    86   58 (67%)    7 (8%)      0.95       0.56[d](#nt128){ref-type="table-fn"}
  Tinnitus                                                53        28 (53%)                     9 (17%)                    87   38 (44%)   12 (14%)     0.29                       0.61
  Pseudo-occlusive syndrome                               53        23 (43%)                     4 (8%)                     87   48 (55%)    7 (8%)      0.18       1.00[d](#nt128){ref-type="table-fn"}
  Infections (bronchitis, rhinitis, conjunctivitis)       53        26 (49%)                     4 (8%)                     87   38 (44%)   9 (10%)      0.54       0.77[d](#nt128){ref-type="table-fn"}
  Olfactive intolerance                                   53        33 (62%)                    10 (19%)                    87   41 (47%)    3 (3%)      0.08     *0.0047* [d](#nt128){ref-type="table-fn"}
  Social interaction                                      53        28 (53%)                     3 (6%)                     86   41 (48%)    6 (7%)      0.55       1.00[d](#nt128){ref-type="table-fn"}
  Depression                                              53        33 (62%)                     4 (8%)                     86   48 (56%)    6 (7%)      0.45       1.00[d](#nt128){ref-type="table-fn"}
  Mobility                                                53        25 (47%)                     5 (9%)                     87   45 (52%)   12 (14%)     0.60                       0.44
  Anaphylactic shock                                      53        26 (49%)                     5 (9%)                     87   41 (47%)    6 (7%)      0.82       0.75[d](#nt128){ref-type="table-fn"}
  Sweat                                                   53        28 (53%)                     5 (9%)                     87   38 (44%)    8 (9%)      0.29       1.00[d](#nt128){ref-type="table-fn"}
  Stomatitis                                              53        23 (43%)                     7 (13%)                    87   28 (32%)   9 (10%)      0.18                       0.61
  Flush                                                   53        31 (58%)                     6 (11%)                    87   45 (52%)    6 (7%)      0.44       0.37[d](#nt128){ref-type="table-fn"}
  Performance status                                      53        33 (62%)                     2 (4%)                     86   49 (57%)   10 (12%)     0.54       0.13[d](#nt128){ref-type="table-fn"}
  Hemorrhoids                                             53        19 (36%)                     2 (4%)                     87   43 (49%)   9 (10%)      0.12       0.21[d](#nt128){ref-type="table-fn"}
  Cough                                                   53        27 (51%)                     1 (2%)                     86   39 (45%)    1 (1%)      0.52       1.00[d](#nt128){ref-type="table-fn"}
  Ear/nose/throat inflammation                            53        14 (26%)                     3 (6%)                     86   25 (29%)    4 (5%)      0.74       1.00[d](#nt128){ref-type="table-fn"}
  Erectile function/ability to make love                  53         5 (9%)                      1 (2%)                     86   19 (22%)   10 (12%)     0.06       0.05[d](#nt128){ref-type="table-fn"}
  Nausea, vomiting                                        53        33 (62%)                     3 (6%)                     87   40 (46%)    2 (2%)      0.06       0.37[d](#nt128){ref-type="table-fn"}
  Diarrhea                                                53        18 (34%)                     2 (4%)                     87   29 (33%)    4 (5%)      0.94       1.00[d](#nt128){ref-type="table-fn"}
  Warts                                                   53        13 (25%)                     1 (2%)                     87   15 (17%)    3 (3%)      0.30       1.00[d](#nt128){ref-type="table-fn"}
  Pain                                                    53        11 (21%)                     0 (0%)                     86   17 (20%)    1 (1%)      0.89       1.00[d](#nt128){ref-type="table-fn"}
  Folliculitis                                            53         5 (9%)                      0 (0%)                     86   15 (17%)    3 (3%)      0.19       0.29[d](#nt128){ref-type="table-fn"}
  Dysuria                                                 53        8 (15%)                      0 (0%)                     86   10 (12%)    1 (1%)      0.55       1.00[d](#nt128){ref-type="table-fn"}

*P*-value calculated between CM and SM by Chi square test except where noted.

Grades 1--4.

Grades 3 and 4 only.

*P*-value calculated by Fisher\'s exact test. Symptoms are listed in the same order as in [Table 4](#pone-0002266-t004){ref-type="table"}. Statistically significant differences (\<0.05) are shown in italics.

Standard measures of disability {#s3d}
-------------------------------

At the same time or subsequent to completing the OPA and AFIRMM questionnaires, the patients were asked to respond to questionnaires to assess standard measures of disability. This included four quantifiable measures of disability (existence of life-threatening anaphalactoid episodes, number of flushes per week, number of stools per day, and number of micturitions per day) and three scores that have been used to assess disability in other diseases, namely, pruritus score, Hamilton score for depression [@pone.0002266-Hedlung1], and QLQ-C30 score, which was designed to measure the quality of life in oncology patients [@pone.0002266-Aaronson1]. Patients were considered to have a disability when they had recurrent life-threatening anaphylactoid episodes (19%), ≥7 episodes of flushing per week (66%), ≥4 stools per day (12%), ≥8 micturitions per day (32%), a pruritus score ≥6 (77%), a Hamilton rating score ≥10 (75%), or a QLQ-C30 score ≥60 (32%) ([Table 7](#pone-0002266-t007){ref-type="table"}). According to these scores, 61% of all responding mastocytosis patients presented at least one disability. Furthermore, there were no significant differences in these seven parameters of disability by clinical form (CM vs. SM; [Table 8](#pone-0002266-t008){ref-type="table"}), the presence or absence of the KIT D818V mutation ([Table 9](#pone-0002266-t009){ref-type="table"}), or the presence or absence of a serum tryptase level ≥20 ng/mL ([Table 10](#pone-0002266-t010){ref-type="table"}).

10.1371/journal.pone.0002266.t007

###### Standard measures of disability.

![](pone.0002266.t007){#pone-0002266-t007-7}

  Parameter                                                         *n*   No. with handicap
  ---------------------------------------------------------------- ----- -------------------
  Existence of recurrent life-threatening anaphylactoid episodes    153       29 (19%)
  ≥7 flushes per week                                               92        61 (66%)
  ≥4 stools per day                                                 90        11 (12%)
  ≥8 micturitions per day                                           92        29 (32%)
  Pruritus score ≥6                                                 90        69 (77%)
  Hamilton scale ≥10                                                88        66 (75%)
  QLQ-C30 ≥60                                                       124       40 (32%)

Data was collected from the 262 patients that participated in the pathophysiological study.

10.1371/journal.pone.0002266.t008

###### Standard measures of disability: comparison by classification.

![](pone.0002266.t008){#pone-0002266-t008-8}

  Parameter                                                         CM     SM      *P*-value[a](#nt130){ref-type="table-fn"}             
  ---------------------------------------------------------------- ---- --------- ------------------------------------------- ---------- ------
  Existence of recurrent life-threatening anaphylactoid episodes    21   3 (14%)                      61                       10 (16%)   1.00
  ≥7 flushes per week                                               8    6 (75%)                      28                       19 (68%)   1.00
  ≥4 stools per day                                                 7    2 (29%)                      28                       4 (14%)    1.00
  ≥8 micturitions per day                                           8    1 (13%)                      28                       8 (29%)    1.00
  Pruritus score ≥6                                                 8    7 (88%)                      27                       19 (70%)   1.00
  Hamilton scale ≥10                                                8    7 (88%)                      26                       22 (85%)   1.00
  QLQ-C30 ≥60                                                       10   4 (40%)                      34                       14 (41%)   1.00

*P*-value calculated by Fisher\'s exact test. Data was collected from the 262 patients that participated in the pathophysiological study.

10.1371/journal.pone.0002266.t009

###### Standard measures of disability: comparison by KIT mutation status.

![](pone.0002266.t009){#pone-0002266-t009-9}

  Parameter                                                         No D816V    D816V     *P*-value             
  ---------------------------------------------------------------- ---------- ---------- ----------- ---------- --------------------------------------
  Existence of recurrent life-threatening anaphylactoid episodes       37      8 (22%)       102      16 (16%)   0.41[a](#nt131){ref-type="table-fn"}
  ≥7 flushes per week                                                  18      13 (72%)      67       45 (67%)   0.68[a](#nt131){ref-type="table-fn"}
  ≥4 stools per day                                                    18      2 (11%)       65       8 (12%)    1.00[b](#nt132){ref-type="table-fn"}
  ≥8 micturitions per day                                              18      5 (28%)       67       21 (31%)   0.77[a](#nt131){ref-type="table-fn"}
  Pruritus score ≥6                                                    18      13 (72%)      66       51 (77%)   0.76[b](#nt132){ref-type="table-fn"}
  Hamilton scale ≥10                                                   18      14 (78%)      63       48 (76%)   1.00[b](#nt132){ref-type="table-fn"}
  QLQ-C30 ≥60                                                          28      9 (32%)       82       23 (28%)   0.68[a](#nt131){ref-type="table-fn"}

*P*-value calculated by Chi-square test.

*P*-value calculated by Fisher\'s exact test.

10.1371/journal.pone.0002266.t010

###### Standard measures of disability: comparison by serum tryptase level.

![](pone.0002266.t010){#pone-0002266-t010-10}

  Parameter                                                         ≤20 ng/ml   \>20 ng/ml   *P*-value             
  ---------------------------------------------------------------- ----------- ------------ ----------- ---------- --------------------------------------
  Existence of recurrent life-threatening anaphylactoid episodes       28        4 (14%)        63       9 (14%)    1.00[b](#nt134){ref-type="table-fn"}
  ≥7 flushes per week                                                  15        12 (80%)       29       17 (59%)   0.16[a](#nt133){ref-type="table-fn"}
  ≥4 stools per day                                                    15        2 (13%)        28       4 (14%)    0.27[b](#nt134){ref-type="table-fn"}
  ≥8 micturitions per day                                              15        5 (33%)        29       5 (17%)    0.74[b](#nt134){ref-type="table-fn"}
  Pruritus score ≥6                                                    14        10 (71%)       28       18 (64%)   0.45[b](#nt134){ref-type="table-fn"}
  Hamilton scale ≥10                                                   14        12 (86%)       27       19 (70%)   0.38[a](#nt133){ref-type="table-fn"}
  QLQ-C30 ≥60                                                          24        10 (42%)       36       11 (31%)   0.82[a](#nt133){ref-type="table-fn"}

*P*-value calculated by Chi-square test.

*P*-value calculated by Fisher\'s exact test. Data was collected from the 262 patients that participated in the pathophysiological study.

Discussion {#s4}
==========

This study was the first large-scale, comprehensive analysis of perceived disability in mastocytosis patients. The study included 363 mastocytosis patients in France identified by the AFIRMM network along with 90 control participants. The patient cohort included a mixture of patients with CM and indolent and aggressive forms of SM but no patients with mast cell leukemia.

According to the OPA score, which was a unidimensional self-assessment of disability, a majority of mastocytosis patients (70%) feel that they suffer from a disability, whereas only a minority of the controls (9%) indicated having a disability. We further examined patients\' self-reported disability using the AFIRMM questionnaire and score, which were designed to provide a more comprehensive analysis of perceived disabilities from mastocytosis. The AFIRMM scores confirmed that most mastocytosis patients feel disabled by their disease symptoms. This perception of disability corresponded with the finding that a majority of mastocytosis patients had at least one of the seven measurable disabilities including life-threatening anaphylactoid episodes, 7 or more episodes of flushing per week, 4 or more stools per day (diarrhea), 8 or more micturitions per day (pollakiuria), a pruritus score of 6 or more, a Hamilton rating score of 10 or more (depression), or a QLQ-C30 score of 60 or more.

Analysis of the severity for the 38 individual symptoms on the AFIRMM questionnaire suggested that mastocytosis patients suffer from a wide variety of symptoms: for at least 32 of the 38 symptoms, there was a significant difference between the number of patients and controls reporting a disability. Analysis of the scores (*Grade*×*Weight*) for each symptom revealed that the 10 symptoms that most contributed to the perception of disability were (in decreasing order) psychological impact, asthenia, pruritus, food allergy/intolerance, erythemateous crisis, muscle and joint pain/cramps, pollakiuria, drug allergy, aerophagia/eruction, and dyspnea/bronchoreactivity. Our results also confirmed the existence of number of previously described symptoms associated with mastocytosis, including fatigue (asthenia), anaphylaxis, sweating, flushing, pruritus, erythemateous crises, epigastric pain, diarrhea, nausea/vomiting, bone pain, headache, memory loss, difficulty with social interactions, reduced performance status, and depression [@pone.0002266-Escribano1], [@pone.0002266-Rogers1]. Importantly, our results reveal that the number of symptoms significantly associated with mastocytosis appears to be even larger than previously considered; for the first time, we provide strong evidence that mastocytosis patients also feel disabled by food and drug allergy/intolerance, muscle/joint pain and cramps, aerophagia/eruction, reduced sexual relations, ocular discomfort, tinnitus, pseudo-occlusive syndrome, infections (bronchitis, rhinitis, and conjunctivitis), olfactive intolerance, reduced mobility, hemorrhoidal inflammation, cough, ear/nose/throat inflammation, and general pain ([Table 11](#pone-0002266-t011){ref-type="table"}).

10.1371/journal.pone.0002266.t011

###### Symptoms significantly associated with mastocytosis according to AFIRMM score.

![](pone.0002266.t011){#pone-0002266-t011-11}

  Previously identified symptoms[a](#nt135){ref-type="table-fn"}              Symptoms not previously reported
  ---------------------------------------------------------------- -------------------------------------------------------
  Fatigue (asthenia)                                                          Food and drug allergy/intolerance
  Anaphylaxis                                                                   Muscle/joint pain and cramps
  Sweating                                                                           Aerophagia/eruction
  Flushing                                                                        Reduced sexual relations
  Pruritus                                                                            Ocular discomfort
  Erythemateous crises                                                                    Tinnitus
  Epigastric pain                                                                 Pseudo-occlusive syndrome
  Diarrhea                                                          Infections (bronchitis, rhinitis, and conjunctivitis)
  Dyspnea/bronchoreactivity                                                         Olfactive intolerance
  Nausea/vomiting                                                                     Reduced mobility
  Bone pain                                                                       Hemorrhoidal inflammation
  Headache                                                                                  Cough
  Memory loss                                                                   Ear/nose/throat inflammation
  Difficulty with social interactions                                                   General pain
  Reduced performance status                                       
  Depression                                                       

Symptoms previously identified as described in references 3, 17, 20.

An important finding from this analysis was that psychological and neurological symptoms appear to be key contributors to disability in mastocytosis. We found that the psychological impact of the skin appearance was the symptom that most contributed to perception of disability in all mastocytosis patients: 72% of patients reported some disability due to this symptom, and 23% considered it severe or intolerable. Asthenia was another very common complaint, with 82% of mastocytosis patients reporting a disability, and a high proportion (28%) describing it as severe or intolerable. Also, patients reported suffering from reduced performance status (52%), difficulty with social interactions (55%), depression (57%), memory loss (66%), headache (69%), and pain (20%). That depression is a common symptom of mastocytosis was confirmed by the finding that more than 70% of all mastocytosis patients had a Hamilton score \>10. Our observation that psychological and neurological effects are common in mastocytosis extends earlier findings by Rogers et al. [@pone.0002266-Rogers1], who found that SM is associated with diminished attention and memory, anger, irritability, and depression, a combination of symptoms that they referred to as an "atypical or mixed organic brain syndrome". Also, a study in the late 1970s by Soter et al. [@pone.0002266-Soter1] reported neuropsychiatric symptoms in five of eight mastocytosis patients, including poor attention span, irritability, fatigue, difficulty in concentrating, headache, inability to work effectively, problems in dealing with other people, and poor motivation. Overall, our results support the notion that the neurologic manifestations of SM are more common than previously thought [@pone.0002266-Boncoraglio1], and they support the suggestion that mastocytosis patients may often be misdiagnosed due the nonspecificity of their neurologic symptoms [@pone.0002266-Escribano1].

In addition, our findings confirm that cutaneous, gastrointestinal, and skeletal symptoms are common to SM [@pone.0002266-Escribano1], [@pone.0002266-Jensen1]. We also found that pulmonary symptoms (i.e., cough and dyspnea/bronchoreactivity) are significantly associated with mastocytosis. In fact, 26% of all mastocytosis patients report suffering from severe or intolerable dyspnea or bronchoreactivity, and this symptom was the tenth most important contributor to overall disability according to the AFIRMM score. Another unexpected finding was that reduced sexual relations was one of the more important symptoms, with as many as 18% of patients describing it as severe or intolerable.

The key finding of this study was that the overall extent of disability and the type and severity symptoms were essentially the same between CM and SM patients. Initially, we found that patients\' overall perception of disability as determined by both the OPA and AFIRMM scores does not depend on the clinical form of the disease. Importantly, we also found that there was no statistical difference between CM and SM in the seven standard measures of disability. These unexpected findings were confirmed when the analyses were limited to patients whose diagnosis of mastocytosis was validated by a careful centralized review of pathological and clinical data. On the basis of these results, we propose that CM and SM and their different subtypes are not distinct diseases but are part of a continuous spectrum of mast cell-related dysfunctions. Furthermore, this implies that the presence of excessive mast cells in extracutaneous tissues such as bone marrow is not helpful for understanding the disability and symptoms--real and/or perceived--of mastocytosis patients.

The KIT D816V mutation has been suggested to correlate with the occurrence of SM in adult patients and to contribute to its progression [@pone.0002266-Valent1], [@pone.0002266-Akin1]. However, there was no difference in disability as measured by OPA score, AFIRMM score, or measurable parameters of disability between patients with and without this mutation. Likewise, for 37 of the 38 symptoms, there was little or no difference in the fraction of patients reporting a disability according to the presence of the D816V mutation. Thus, the type and severity of mastocytosis symptoms appears to be unrelated to the presence of the D816V KIT mutation.

We also did not find a significant difference in the overall perception of disability (OPA and AFIRMM scores) or standard measures of disability according to the serum tryptase level (≤20 vs. \>20 ng/mL). Likewise, the serum tryptase level appeared to have no bearing on the severity of the 38 individual symptoms as measured by the AFIRMM score or the standard measures. Because our assay measured total tryptase levels, which is an indicator of total mast cell burden [@pone.0002266-Schwartz2], it appears that the type and severity of most symptoms are unrelated to elevated mast cell numbers. Accordingly, we expect that the level of activated, mature tryptase, which is a measure of mast cell activation [@pone.0002266-Schwartz2], will be more useful than total serum tryptase for understanding the pathogenesis of mastocytosis.

Conclusions {#s4a}
-----------

In summary, these results suggest that the existing classification system for mastocytosis does not help understand patients\' overall perception of disability, their individual symptoms, or their impact on the quality of life. It appears that the presence of elevated mast cell numbers in bone marrow or extracutaneous tissues, an elevated serum tryptase level, and the D816V KIT mutation has little or no bearing on the type or severity symptoms. Given these results, we suspect that the symptoms of indolent mastocytosis are mostly unrelated to mast cell proliferation or infiltration; rather, it appears that the symptoms are the result of mast cell activation and the systemic release of mediators. On this basis, we propose an alternative classification system to help in the treatment of mastocytosis patients, namely, that (i) mast cell leukemia and aggressive mastocytosis be considered and treated separately from indolent forms and (ii) that indolent mastocytosis be classified and treated simply according to the patient\'s perception of disability due to symptoms of the disease.

Another important finding was that, although none of the symptoms are specific to the disease, the number associated with mastocytosis is even higher than previously realized and includes some symptoms that have been largely overlooked, especially neuropsychiatric symptoms. Given the wide variety and nonspecificity of these symptoms, we suspect that many mastocytosis patients are misdiagnosed and that the prevalence of mastocytosis is therefore higher than previously considered.

Finally, as part of the current study, we developed and validated a questionnaire and composite score for assessing patients\' perception of disability in mastocytosis (AFIRMM score). This scoring system should be useful in evaluating the efficacy of mastocytosis treatments in future clinical trials and for further understanding the nature of symptoms and disability from mastocytosis.
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